Domain Therapeutics SA
Domain Therapeutics SA
Explore linked clinical trials.2 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-05-06 | NCT06819735 | |
| A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Not yet recruiting | Early phase 1 | 2025-10-09 | NCT07213882 |